BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35094231)

  • 1. A critical analysis of deficiencies in the quality of information contained in prostate multiparametric MRI requests and reports.
    Cullivan O; Roche E; Hegazy M; Taha M; Durkan G; O'Malley P; McCarthy P; Dowling CM
    Ir J Med Sci; 2023 Feb; 192(1):27-31. PubMed ID: 35094231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA.
    Müller S; Lilleaasen G; Sand TE; Løfsgaard L; Estop-Garanto M; Helgø D; Sund P; Mygland V
    World J Urol; 2018 May; 36(5):687-691. PubMed ID: 29508048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
    Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
    J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
    Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
    World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
    Haack M; Miksch V; Tian Z; Duwe G; Thomas A; Borkowetz A; Stroh K; Thomas C; Haferkamp A; Höfner T; Boehm K
    World J Urol; 2022 Dec; 40(12):2947-2954. PubMed ID: 36318314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
    Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a Rule-Based Algorithm in the Assessment of Standardized Reporting in PI-RADS.
    Zhang D; Neely B; Lo JY; Patel BN; Hyslop T; Gupta RT
    Acad Radiol; 2023 Jun; 30(6):1141-1147. PubMed ID: 35909050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
    Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
    Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    Sorce G; Stabile A; Lucianò R; Motterle G; Scuderi S; Barletta F; Pellegrino F; Cucchiara V; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Jeffrey Karnes R; Guccini I; Briganti A
    BJU Int; 2022 Feb; 129(2):201-207. PubMed ID: 34038039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
    Kotb AF; Spaner S; Crump T; Hyndman ME
    World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
    [No Abstract]   [Full Text] [Related]  

  • 19. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
    Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.